Immuno-pharma company AIM ImmunoTech Inc (NYSE American:AIM) reported on Wednesday that the first subject has been dosed at Erasmus Medical Center in the Netherlands for the Phase 1b/2 DURIPANC study, evaluating Ampligen (rintatolimod) with AstraZeneca's (STO:AZN) (LON:AZN) (Nasdaq:AZN) Imfinzi (durvalumab) for late-stage pancreatic cancer.

The Phase 1b part aims to establish safety, and is expected to conclude within six months, while Phase 2 aims to determine the clinical benefit rate of the combination therapy.

Prof. Casper H.J. van Eijck, MD, PhD, pancreato-biliary surgeon at Erasmus Medical Center highlighted the potential of this combination to positively impact tumour regression and patient survival.

The study targets enrolment of up to 18 subjects in Phase 1b and up to 25 in Phase 2. The treatment regimen involves Ampligen via IV infusion twice weekly for 6 weeks, with dose escalation, and durvalumab administered every 4 weeks for up to 48 weeks or until confirmed disease progression.